Valentina Echeverria Moran, Bioch, MS, Ph.D.GCSRTP.

My goal is to transform scientific discoveries into effective solutions. Professor Fac. Medicine, Universidad San Sebastian, Chile. Scientist, Bay Pines Veterans Affairs (VA) Health Care System, USA (WOC). Cell, +1-347-***-****, E-mail: adytrc@r.postjobfree.com Biochemist, Ph.D. in Biological Sciences, Basic and ClinicaL Neuroscientist. Certificated in Clinical Research design, implementacion, Monitoring and analysis. Her work in the USA at the Bay Pines VAHCS and Chile as a professor has focused on Psychiatric and Neurodegenerative disorders. Using animal and cellular disease models, she and her team discovered relevant mechanisms leading to neuroinflammation and mental dysfunction and advanced potential new therapies for mental conditions, including Alzheimer's disease (AD), Depression, Anxiety, and Posttraumatic stress disorder (PTSD). This research has resulted in more than 100 publications, ten grants awards, and six approved patents for using Cotinine to enhance neurogenesis, diminish neuroinflammation, and neurodegeneration to treat and prevent PTSD, Major depression, and cognitive impairment induced by these conditions as well as chemotherapy, and other mental disorders such as Parkinson's disease and Down's syndrome. Her current goal is to further advance in the mechanism leading to cognitive impairment and translate these discoveries into clinical practice. This dream motivated her to continue her education at Harvard Medical School in Clinical research and epidemiological analysis.

ACCOMPLISHMENTS

• Using animal disease models, my teams and I have demonstrated the feasibility of diminishing symptoms including cognitive impairment, and chronic pain,and halting the development of AD, Parkinson’s disease (PD), chronic stress, PTSD, and “Brain fog” caused by cancer treatment using Cotinine, and the Raf inhibitors including caffeine sorafenib and GW5074.

• Obtained and successfully managed 11 research grant awards in the USA, and Chile

• Five US Patents Granted in Biomedicine.

• Published more than 117 publications (93 in peer-reviewed journals)

• 4315 citations. Indexes hi =39, i10 =83 (Valentina Echeverria Moran - Google Scholar)

• Mentored 24 research fellows and taught Neuroscience and Biochemistry courses for Undergraduate and Graduate students in Spain, Canada, USA., and Chile. EXPERTISE Management of Scientific research (group leader). International collaborations. Medical education online. Clinical Trials Experimental design, Genetic epidemiology, Data analysis using STATA, Regression analysis, Randomization, Ethics. Innovation, Grant writing, RCT monitoring. Surveys design, Advanced epidemiology, Secondary Analysis, Metaanalysis. Knowledgeable (PhD level) in Molecular and cellular Biology, Microbiology (MS level), Pharmacology, and Ethnopharmacology. Molecular mechanisms of neuroinflammation, learning, memory, neurodegeneration, oxidative stress, and clinical research. Expert in AD, PD, Traumatic brain Injury, PTSD, depression. Fish stress.

EDUCATION

University of Concepcion, Chile Biochemist Biochemistry 1984-1991 University of Concepcion, Chile M.Sc. Biochemistry 1991-1996 University of Concepcion, Chile Ph.D. Biological Sciences 1994-1999 National Center for Biotechnology, Spain Post-Doctoral Neuroscience 1999-2001 McGill University, Canada Post-Doctoral Neuroscience 2001-2003 Johns Hopkins University, USA Post-Doctoral Neuroscience 2003-2005 Harvard Medical School, USA 1-Year Certificate Clinical research 2022-2023. Global Clinical Scholars Research Training Program (GCSRTP). POSITIONS AND EMPLOYMENT

2007- Present Scientist, Bay Pines Veterans Affairs Healthcare System (VHACS), FL, USA (WOC)(GS13). Works in Research and Innovation in Veternas Health Problems. Directed scientificallty a 5-7 team of research associates and undergraduate and graduate students in Biomedical research. Participate and lead international clinical teams working on Grant writing and IND applications for New drugs to be used in clinical research.

2015-Present Professor, Universidad San Sebastian, Concepcion, Chile. Lead Research and Innovation in Neurological conditions such as PTSD and AD. Directed scientificallty a 5-7 team of research associates and undergraduate and graduate and Postdoctoral scientist working in Biomedical research 2022-2023 Scientist Defense Health Program (Ciconix). Site clinical Scientist lead for the Traumatic Brain Injury Center of Excellence (TBICoE) Program, FL.

Worked in Data analysis, Grant and manuscript writing in Traumatic brain Injury. 2005-06 Assoc. Res. Scientist. Department of Pathology, Columbia University, New York City, USA. 2000-01 Research Scientist. National Center for Biotechnology CNB (CSIC), Madrid, Spain. HONORS AND AWARDS

06/2022-2023 Partial fellowship to attend the 1-Year Certificate Postgraduate Medical Education "Global Clinical Scholars Research Training Program". Clinical research: Epidemiology, Clinical Trials experimental design, Genetic epidemiology, Data analysis using STATA, Regression analysis, Randomization, Ethics, Innovation, Grant writing, data analysis, RCT monitoring. Surveys design, Advanced epidemiology. Secondary Analysis, Metaanalysis.

2019-2023 Research award, University San Sebastian, Chile (4 years monetary award) 2014 Nominated by the Bay Pines Veterans Affairs Healthcare System as a Notable Biomedical Scientist 2012 Travel award to attend the Society for Neuroscience. Bay Pines Foundation Inc. 2008 Travel Award to present at the International Conference of Alzheimer's Disease (ICAD), American Alzheimer's Association.

2007-2021 Eleven Grant Awards

2004 Young Investigator Educational Enhancement Award. American Society of Neurochemistry 2000-01 International contract from the Ministry of Science and Technology (Spain). National Center for Biotechnology (CSIC). Madrid, Spain (Intl. Competition) 1999 Teaching Assistant Doctoral Fellowship. Graduate School. University of Concepción, Chile. 1995-98 Doctoral fellowship from National Commission of Science and Technology, CONICYT, Chile. 1993 International Fellowship to participate in the In Vitro Cell Biology and Biotechnology Program

(700hs). SUNY. Plattsburgh, NY. The USA.

1991-94 Teaching Assistant Graduate Fellowship. Graduate School, University of Concepción, Chile. PROFESSIONAL AFFILIATIONS

2023 Harvard Alumni Association (HAA).

2023 Member study section ANID Start Up. Medicina G1 2022. (Segundo semestre) 2022 Member study section ANID Fondecyt Postdoctoral grants. Medicina G1 2022. (First semestre) 2021 Member del comite de Fondecyt regular. Biology 3 2021. (Segundo semestre) 2017-Present Royal Society of Medicine London, UK. Overseas Member 2016-2017 Scientific Adviser NICER Foundation LLC. (Narcolepsy's cause foundation) 2013-Present Member, American Chemistry Society (ACS) 2005-Present Member, New York Academy of Sciences

2004-Present Member, American Society of Neurosciences EDITORIAL BOARDS

American Journal of Alzheimer's Disease and Other Dementias; Journal of Alzheimer's Disease Associate Editor); Frontiers in ethnopharmacology; Neural Regeneration Research; World Journal of Pharmacology, Behavioral sciences; Frontiers in Pharmacology; American Journal of Neurodegenerative Disease; International Neuropsychiatric Disease Journal; Chronic Diseases – International

Editor (>15 peer-reviewed journals); Ad Hoc Reviewer (32 journals). Editor Roles at Frontiers.org:

Associate Editor in Ethnopharmacology

Guest Associate Editor: Frontiers in Aging Neuroscience Archive, Frontiers in Neurodegeneration; in Molecular Signalling and Pathways; in Cellular and Molecular Mechanisms of Brain-aging; Alzheimer's Disease and Related Dementias. Review Editor: frontiers in Aging Neuroscience Archive; Frontiers in Neurotrauma; Frontiers in neuroscience; Grant Reviewer:

1. American Alzheimers Association.

2. Parkinson’s.org, UK. 2018.

3. External referee Cochrane Dementia and Cognitive Improvement Group. 2020. 4. Alzheimer Forschung Initiative e.V. (Germany), Fondation Vaincre Alzheimer (France) and Alzheimer Nederland (The Netherlands). The European Research Grant Cycle,2021. 5. Member Committee Roster ANID Grant Fondecyt regular. Biology 3. 2021 6. Member Committee Roster ANID Grant Fondecyt regular. Medicina G1 2022 7. Member Committee Roster ANID Grant Startup Ciencia 2023 PEER-REVIEWED PUBLICATIONS

1. Echeverria V, Mondaca MA, Montoya R, Bunster M, Cid H. Characterization of a plasmid codifying the synthesis of a beta-lactamase produced by Shigella flexneri. Microbios 76:161–166, 1993. 2. Echeverria V, Olate J, Cid H. Partial DNA Sequence of a beta-lactamase produced by a Shigella flexneri strain. Microbios. 83: 107–117, 1995.

3. Torrejón M, Echeverria V, Retamales G, Herrera L, Hinrichs M, Olate J. Molecular cloning and expression of adenylyl cyclase from Xenopus laevis oocytes. FEBS Letters. 404: 91–94, 1997. 4. Torrejón M, Geneviere A.M, Echeverria V, Guzmán L, Hinrichs M, Olate J. The C2 cytosolic loop of adenylyl cyclase interacts with the activated form of Gsalpha. FEBS Letters. 441: 437-440, 1998. 5. Echeverria V, Hinrichs MV, Torrejón M, Ropero S, Toro MJ, Olate J. Mutagenesis in the switch IV of the helical domain of the human Gsa reduces its GDP/GTP exchange rate. J Cell Biochem. 76(3): 368-375, 1999. 6. Ledo, F., Link, W. A., Carrión, A. M., Echeverria, V., Mellström, B., & Naranjo, J. R. The DREAM-DRE interaction: key nucleotides and dominant negative mutants. Biochimica et biophysica acta, 1498(2-3), 162–168. https://doi.org/10.1016/s0167-4889(00)00092-6. 2000 7. Echeverria V, Cuello AC. Intracellular Abeta amyloid, a sign for worse things to come? Mol Neurobiol. 26 (2-3): 299- 316, 2002

8. Echeverria V, Ducatenzeiler A, Alohen L, Janne J, Grant S, Wandosell F, Muro A, Baralle F, Li H, Duff K, Szyf M, Cuello AC. Rat transgenic models with a phenotype of intracellular Abeta accumulation in hippocampus and cortex. J. Alzheimer’s Dis. 6(3): 209-19, 2004

9. Echeverria V, Dowd E, Ducatenzeiler A, Alohen L, Janne J, Grant S, Muro A, Baralle F, Li H, Hartmann, T, Cuello, AC. Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience. 129(3): 583, 2004

10. Echeverria V, Greenberg LD, Doré, S. Expression of prostaglandin E2 synthases in mouse postnatal cortical neurons. Ann NY Acad Sci. 1053:460-71. doi: 10.1111/j.1749-6632.2005.tb00056.x. 2005 11. Echeverria V, Ducatenzeiler A, Chen CH, Cuello AC. Endogenous beta- amyloid peptide synthesis modulates cAMP response element-regulated gene expression in PC12 cells. Neuroscience. 135(4): 1193-1202, doi: 10.1016/j.neuroscience.2005.06.057. 2005

12. Echeverria V, Clerman A, Doré, S. Stimulation of PGE. receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur J Neurosci. 22(9): 2199-2206. doi: 10.1111/j.1460- 9568.2005.04427.x..2005

13. Ahmad M, Saalem S, Zhuang H, Echeverria V, Sapirstein A, Doré, S. 1-hydroxyPGE1 reduces infarction volume in mouse transient cerebral Ischemia. Eur J Neurosci. 23(1):35-42. doi: 10.1111/j.1460-9568.2005.04540.x 2006 14. Ahmad, A. S., Zhuang, H., Echeverria, V., & Doré, S. Stimulation of prostaglandin EP2 receptors prevents NMDA- induced excitotoxicity. Journal of Neurotrauma. 23(12): 1895-1903. doi.org/10.1089/neu.2006. 23. 1895. 2006 15. Echeverria V, Powell D, Arancio O. Oligomers of beta-amyloid peptide block BDNF-induced Arc expression in cultured cortical neurons. Curr Alzheimer Research. 4 (5):518-52. doi: 10.2174/156720507783018190. 2007 16. Citron, B A., Dennis, J S., Zeitlin, RS, Echeverria V. Transcription factor Sp1 dysregulation in Alzheimer's disease. J Neuroscience Res. Aug 15:86(11): 2499-504. doi: 10.1002/jnr.21695. 2008 17. Echeverria V, Burgess S, Dickson A, Arendash WG, Citron AB. Raf inhibition is protect cortical cells against beta-amyloid beta toxicity. Neuroscience Lett. 444 (1):92-96. doi: 10.1016/j.neulet.2008.07.092. Epub 2008 Aug 8.2008 18. Echeverria Moran V, Gamble-George J, Burgess S, Dickson A, Mamcarz M, Arendash GW P4-303: Sorafenib as a therapeutic agent against Alzheimer's disease. Alzheimer's and Dementia. 4(4).2008 19. Arendash W.G, Mori T, Mamcarz M, Dickson A, Runfeldt M, Rezai-Zadeh K, Citron B, Tan J, Lin X, Cao Ch, Echeverria V, and Potter H. Caffeine reverses cognitive impairment and decreases brain Aβ levels in aged Alzheimer's disease mice. J Alzheimer's Disease. 17(3):661-80. doi: 10.3233/JAD-2009-1087. 2009. 20. Echeverria V, Burgess S, Gamble-George J, Zeitlin RS, Mamcarz M, Cao C, Arendash WG. Sorafenib inhibited cRaf-1/NF- kappaB pathway and restored working memory in aged APPswe mice. Neuroscience. 162 (4):1220-31. doi: 10.1016/j.neuroscience.2009.05.019.2009.

21. Burgess S and Echeverria V. Raf Inhibitors as Therapeutic Agents against Neurodegenerative Diseases CNS Neurol Disord Drug Targets. 9(1):120-7. doi: 10.2174/187152710790966632. 2010 22. Echeverria V, Zeitlin R, Burgess S, Patel S, Barman A, Thakur G, et al. Cotinine Reduces Amyloid beta Aggregation and Improves Memory in Alzheimer's Mice. J. Alzheimer's Disease, 24(4), 817-835. 2011 23. Zeitlin R, Patel S, Burgess S, Arendash GW, Echeverria V. Caffeine Induces Beneficial Changes in PKA Signaling and JNK and ERK Activities in the Striatum and Cortex of Alzheimer's transgenic Mice.Brain Research.1417:127-36. 2011 24. Zeitlin R, Patel S, Solomon R, Tran J, Weeber EJ, and Echeverria V. Cotinine Enhances the Extinction of Contextual Fear Memory and Reduces Anxiety after fear conditioning. Behavioral Brain Research. 228(2):284-93. 2012 25. Echeverria V, and Zeitlin R. Cotinine: a potential new therapeutic agent against Alzheimer's disease. CNS Neuroscience

& Therapeutic. 18(7):517-23. 2012

26. Moran Echeverria V. Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption. Front Pharmacol. 3:173. 2012

27. Echeverria Moran V. Brain effects of Nicotine and derived compounds. Front. Pharmacol. 4:60. doi: 10.3389/fphar.2013.00060. eCollection 2013. PMID: 237*****-**. Grizzell JA, Iarkov A, Holmes R, Mori T, Echeverria V. Cotinine reduces depressive-like behavior, working memory deficits, and synaptic loss associated with chronic stress in mice. Behav. Brain Res. 268:55-65. 2014 29. Patel S, Grizzell J A, Holmes R, Zeitlin R, Solomon R, Sutton T. L, Rohani A, Charry L, Iarkov A, Mori T and Echeverria Moran V. Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice. Frontiers in Aging Neurosci. doi:10.3389/fnagi.2014.00162. 2014 30. Grizzell JA, Iarkov A, Holmes R, Mori T, Echeverria V. Cotinine reduces depressive-like behavior, working memory deficits, and synaptic loss associated with chronic stress in mice. Behav Brain Res. 268:55-65. 2014 31. Grizzell JA, Mullins M, Iarkov A, Rohani A, Charry L and Echeverria V. Cotinine Reduces Depressive-Like Behavior and Hippocampal Vascular Endothelial Growth Factor Downregulation After Forced Swim Stress in Mice. Behavioral Neuroscience. 128(6), 713-721. doi: 10.1037/bne0000021. 2014 32. Grizzell JA and Echeverria V. New Insights into the Mechanisms of Action of Cotinine and its Distinctive Effects from Nicotine". Neurochemical Research. 40:2032–2046. doi: 10.1007/s11064-014-1359-2. 2015 33. Barreto GE, Yarkov A, and Echeverria V. Beneficial effects of nicotine, Cotinine and its metabolites as potential agents for Parkinson's disease. Front Aging Neurosci.6:340. doi:10.3389/fnagi.2014.00340. 2015 34. Barreto G, Yarkov A, Gjumrakch A, Echeverria V. Nicotine-derived compounds as therapeutic tools against Posttraumatic stress disorder. Curr Pharm Des. 21(25): 7-14. 2015 35. Gjumrakch A, Daza J, Solís-Herrera A, Arias-Esparza M, Morales L, Echeverria V, Barreto GE. Nanoparticles as alternative strategies for drug delivery to the Alzheimer Brain. CNS Neurol Disord Drug Targets. 14(9):1235-42. 2015 36. Cabezas R, Avila MF, Vega-Vela NE, Echeverria MV, González J, Hidalgo OA, Brito-Santos A, Barreto GE. Growth Factors and Astrocytic Metabolism: Possible Roles for Platelet-derived Growth Factor. Med Chem.12(3):204-10. 2016. 37. Echeverria V. Neuroinflammation a common link in neurodegenerative neurological and psychiatric disorders. Editorial. Curr Pharm Des. 22(10):1293. 2016

38. Echeverria V. Yarkov A, Gjumrakch A. Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease. Prog Neurobiol. 144:142-57. 2016 39. Echeverria MV, Grizzell JA, Barreto GE. Neuroinflammation: a therapeutic target of Cotinine for the treatment of psychiatric disorders. Curr Pharm Des. 22(10):1324-33. 2016 40. Jurado-Coronel JC, Echeverria MV, Gonzalez J, Barreto GE. Targeting the nicotinic acetylcholine receptors (nAChRs) in astrocytes as a potential therapeutic target in Parkinson’s disease. Curr Pharm Des. 22(10): 1305-11. 2016. 41. Garzón D, Cabezas R, Vega N, Ávila-Rodriguez M, Gonzalez J, Rosa Gómez M, Echeverria V, Aliev G, Barreto, GE. Novel Approaches in Astrocyte Protection: from Experimental Methods to Computational Approaches. J Molecular Neurosci. 58(4):483-92. 2016.

42. Lanussa OH, Ávila-Rodriguez M, García-Segura L M, González J, Echeverria V, Aliev G and Barreto GE. Microglial Dependent Protective Effects of Neuroactive Steroids. CNS Neurol Disord Drug Targets. 15(2):242-9. 2016. 43. Jurado-Coronel JC, Ávila-Rodriguez M, Echeverria V, Hidalgo OA, Gonzalez J, Aliev G and Barreto GE. Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease. CNS Neurol Disord Drug Targets. 2016; 15(3): 292-300. 2016.

44. González-Giraldo Y, Echeverria V, Barreto G E. Neuroprotective effects of Telomerase: A Potential Therapeutic Target in the CNS. Ageing Research Reviews. 28:37-45. 2016 45. Mendoza C, Aliev G, Barreto GE, Echeverria V. Role of neuroinflammation and sex hormones in war-related PTSD. Mol Cell Endocrinol. 434:266-77. 2016.

46. Toro N, Garcia-segura LM, Echeverria V, Barreto GE. Testosterone protects mitochondrial function and regulates neuroglobin expression astrocytic cells exposed to glucose deprivation. Front. Aging Neurosci. 8:152. 2016. 47. Vega-Vela NE, Osorio D, Ávila-Rodriguez M, J Gonzalez J, García-Segura LM, Echeverria V, Barreto GE. L-type calcium channels modulation by estradiol. Mol Neurobiol. Rev. PMID: 27525676. 2016. 48. Baez E, Echeverria V, Cabezas R, Barreto GE, García-Segura LM. Protection by neuroglobin expression in brain pathologies. Front Neurology. September 12. 7:146. doi: 10.3389/fneur.2016.00146. 2016. 49. Iarkov A, Appunn D, Echeverria V. Post-treatment with Cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats. Cancer Chemotherapy and Pharmacology. 78(5):1033-39. 2016 50. Barreto GE, Avila-Rodriguez M, Foitzick M, Aliev G, Echeverria V. Advances in Medicinal Plants with Effects on Anxiety Behavior Associated with Mental and Health conditions. Curr. Med. Chem. 24(4): 411-423. 2017 51. Martin-Jiménez CA, Gaitán-Vaca DM, Echeverria V, González J, Barreto GE. Relationship Between Obesity, Alzheimer's Disease, and Parkinson's Disease: An Astrocentric View. Mol Neurobiol .54(9):7096- 7115.doi:10.1007/s12035-016-0193-8. 2017

52. Singh S, Barreto G, Aliev G and Echeverria V. Ginkgo biloba as an alternative medicine for dementia and other psychiatric disorders. Curr. Drug Metab. 18(2):112-119. doi: 10.2174/ 1389200217666161201112206. 2017 53. Ghotme KA, Barreto GE, Echeverria V, Gonzalez J, Bustos RH, Sanchez M, Leszek J, Yarla NS, Gomez RM, Tarasov VV, Ashraf GM, Aliev G. Gliomas: New Perspectives in Diagnosis, Treatment and Prognosis. Curr Top Med Chem. 17(12):1438-1447. doi: 10.2174/1568026617666170103162639. PMID: 28049399. 2017 54. Mazo NA, Echeverria V, Cabezas R, Avila-Rodriguez M, Tarasov VV, Yarla NS, Aliev G, Barreto GE. Medicinal Plants as Protective Strategies Against Parkinson's Disease. Curr Pharm Des. 23(28):4180-4188. doi: 10.2174/1381612823666170316142803. PMID: 28302024. 2017 55. Barreto GE, Gomez RM, Bustos RH, Forero DA, Aliev G, Tarasov VV, Yarla NS, Echeverria V, Gonzalez J. Approaches of the Transcriptomic Analysis in Astrocytes: Potential Pharmacological Targets. Curr Pharm Des.23(28):4189-97. 2017. 56. Cabezas R, Vega-Vela NE, González-Sanmiguel J, González J, Esquinas P, Echeverria V, Barreto GE. PDGF-BB Preserves Mitochondrial Morphology, Attenuates ROS Production, and Upregulates Neuroglobin in an Astrocytic Model Under Rotenone Insult. Mol Neurobiol. doi: 10.1007/s12035-017-0567-6. 2017. 57. Bachurin SO, Shevtsova EF, Makhaeva GF, Grigoriev VV, Boltneva NP, Kovaleva NV, Lushchekina SV, Shevtsov PN, Neganova ME, Redkozubova OM, Bovina EV, Gabrelyan AV, Fisenko VP, Sokolov VB, Aksinenko AY, Echeverria V, Barreto GE, Aliev G. Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment. Sci Rep. 7:45627. doi: 10.1038/srep45627. PMID: 28358144; PMCID: PMC5372361. 2017 58. Echeverria V, Barreto GE, Ávila-Rodriguez M, Tarasov VV, Aliev G. Is VEGF a key target of Cotinine and other potential therapies against Alzheimer disease? Curr Alzheimer Res. 14 (11): 115*-****-**** 59. Grizzell JA, Patel S, Barreto GE, Echeverria V. Cotinine improves visual recognition memory and decreases cortical Tau phosphorylation in the Tg6799 mice. Prog Neuropsychopharmacol Biol Psychiatry.78:75-81. 2017 60. Perez-Urrutia N, Alvarez N, Oliverus-Matus P, Echeverria F., Barreto, GE, Iarkov A, Echeverria V. Intranasal cotinine improves memory and reduces depressive-like behavior, and GFAP+ cells loss induced by restraint stress in mice. Exp Neurol. 295: 211-221. 2017.

61. Baez E, Guio-Vega GP, Echeverria V, Sandoval-Rueda DA, Barreto GE. 4'-Chlorodiazepam Protects Mitochondria in T98G Astrocyte Cell Line from Glucose Deprivation. Neurotox Res. 32(2):163-171. doi: 10.1007/s12640-017-9733-x. Epub 2017 Apr 13. PMID: 28405935. 2017

62. González-Giraldo Y, Garcia-Segura LM, Echeverria V, Barreto GE. Tibolone Preserves Mitochondrial Functionality and Cell Morphology in Cells Treated with Palmitic Acid. Mol Neurobiol. May;55(5):4453-4462. 2017. 63. Martin-Jiménez, C A., García-Vega, Á., Cabezas, R., Aliev, G., Echeverria, V., González, J., & Barreto, G. E. Astrocytes and endoplasmic reticulum stress: A bridge between obesity and neurodegenerative diseases. Progress in neurobiology, 158, 45-68. doi.org/10.1016/j.pneurobio.2017.08.001. 2017 64. Baez-Jurado E, Vega GG, Aliev G, Tarasov VV, Esquinas P, Echeverria V, Barreto GE. Blockade of Neuroglobin Reduces Protection of Conditioned Medium from Human Mesenchymal Stem Cells in Human Astrocyte Model (T98G) Under a Scratch Assay. Mol Neurobiol. 55(3):2285-2300. doi:10.1007/s12035-017-0481-y. 2018. 65. Gąsiorowski K, Brokos B, Echeverria V, Barreto G E, Leszek, J. RAGE-TLR crosstalk sustains chronic inflammation in neurodegeneration. Mol Neurobiol. 55(2):1463-1476. 2018. 66. Jurado-Coronel JC, Cabezas R, Ávila Rodríguez MF, Echeverria V, García-Segura LM, Barreto GE. Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. Front Neuroendocrinol. 50:18-30. doi: 10.1016/ j.yfrne.2017.09.002. 2018. 67. Hidalgo-Lanussa O., Ávila-Rodriguez M., Baez-Jurado E., Jairo Zamudio., Echeverria V, Garcia-Segura L.M, Barreto G. E. Tibolone Reduces Oxidative Damage and Inflammation in Microglia Stimulated with Palmitic Acid through Mechanisms Involving Estrogen Receptor Beta. Mol Neurobiol. 55(7):5462-5477. 2018. 68. Baez-Jurado E, Hidalgo-Lanussa O, Guio-Vega G, Ashraf GM, Echeverria V, Aliev G, Barreto GE. Conditioned Medium of Human Adipose Mesenchymal Stem Cells Increases Wound Closure and Protects Human Astrocytes Following Scratch Assay in vitro. Mol Neurobiol. 55(6):5377-5392. 2018. 69. Mendoza C, Barreto G. E, Iarkov A, Tarasov V V, Aliev G, & Echeverria V. Cotinine: A Therapy for Memory Extinction in Post-traumatic Stress Disorder. Mol Neurobiol, 55(8), 6700–6711.doi.org/10.1007/s12035-018-0869-3. 2018 70. Ashraf JM, Ansari MA, Fatma S, et al. Inhibiting Effect of Zinc Oxide Nanoparticles on Advanced Glycation Products and Oxidative Modifications: a Potential Tool to Counteract Oxidative Stress in Neurodegenerative Diseases. Mol Neurobiol. 55(9):7438-7452. doi:10.1007/s12035-018-0935-x. 2018 71. Alvarez-Ricartes N, Oliveros-Matus P, Mendoza C, Perez-Urrutia N, Echeverria F, Iarkov A, Barreto GE and Echeverria V. Intranasal cotinine plus krill oil, facilitates fear extinction, decreases depressive-like behavior, and increases hippocampal calcineurin levels in mice. Mol Neurobiol. 55(10):7949-7960. doi:10.1007/s12035-018-0916-0. 2018 72. Areiza-Mazo N, Robles J, Zamudio-Rodriguez JA, Giraldez L, Echeverria V, Barrera-Bailon B, Aliev G, Sahebkar A, Ashraf GM, Barreto GE. Extracts of Physalis peruviana protect astrocytic cells under oxidative stress with rotenone". Front Chem. 6:276. doi: 10.3389/ fchem.2018.00276. 2018. 73. Baez-Jurado E, Rincón-Benavides MA, Hidalgo-Lanussa O, Guio-Vega G, Ashraf G M, Sahebkar A, Echeverria V, Garcia- Segura LM, Barreto G E. Molecular mechanisms involved in the protective actions of Selective Estrogen Receptor Modulators in brain cells. Front Neuroendocrinol. 52:44-64. doi:10.1016/j.yfrne.2018.09.00. 2019 74. Mendoza C, Perez-Urrutia N, Alvares-Ricarteza N, Barreto G, Pérez-Ordás Rl, Iarkov A and Echeverria V. Cotinine plus krill oil decreased depressive behavior, and increased astrocytes survival in the hippocampus of mice subjected to restraint stress. Front Neurosci. 12:952. doi:10.3389/fnins.2018. 00952. 2018 75. Jurado-Coronel, J. C., Loaiza, A. E., Díaz, J. E., Cabezas, R., Ashraf, G. M., Sahebkar, A., Echeverria, V., González, J., & Barreto, G. E. (E)-Nicotinaldehyde O-Cinnamyloxime, a Nicotine Analog, Attenuates Neuronal Cells Death Against Rotenone-Induced Neurotoxicity. Mol Neurobiol.56(2), 1221–1232.doi.org/10.1007/s12035-018-1163-0. 2019 76. Martin-Jiménez C, Gaitán-Vaca DM, Areiza N, Echeverria V, Ashraf GM, González J, Sahebkar A, Garcia-Segura LM, Barreto GE. Astrocytes Mediate Protective Actions of Estrogenic Compounds after Traumatic Brain Injury. Neuroendocrinology. 108(2):142-160. doi:10.1159/000495078. 2019 77. Vesga-Jimenez, DJ., Hidalgo, O., Baez, E., Echeverria, V., Barreto, GE. Raloxifene attenuates oxidative stress and preserves mitochondrial function in astrocytic cells upon glucose deprivation". Journal of Cellular Physiology. 234(3):2051-2057. doi: 10.1002/jcp.27481. 2019

78. González-Giraldo Y, Forero DA, Echeverria V, Garcia-Segura LM, & Barreto, GE. Tibolone attenuates inflammatory response by palmitic acid and preserves mitochondrial membrane potential in astrocytic cells through estrogen receptor beta. Molecular and cellular endocrinology 486, 65-78. doi.org/10.1016/j.mce.2019.02.017. 2019 79. Baez-Jurado, E., Hidalgo-Lanussa, O., Barrera-Bailón, B., Sahebkar, A., Ashraf, G. M., Echeverria, V., & Barreto, G. E. Secretome of Mesenchymal Stem Cells and Its Potential Protective Effects on Brain Pathologies. Molecular neurobiology. 56(10), 6902–6927.https://doi.org/10.1007/s12035-019-1570-x. 2019 80. Baez-Jurado, E., Guio-Vega, G., Hidalgo-Lanussa, O., González, J., Echeverria, V., Ashraf, G. M., Sahebkar, A., & Barreto, G. E. Mitochondrial Neuroglobin Is Necessary for Protection Induced by Conditioned Medium from Human Adipose- Derived Mesenchymal Stem Cells in Astrocytic Cells Subjected to Scratch and Metabolic Injury. Molecular neurobiol, 56(7), 5167–5187. doi.org/10.1007/s12035-018-1442-9. 2019 81. Cabezas, R., Baez-Jurado, E., Hidalgo-Lanussa, O., Echeverria, V., Ashrad, G. M., Sahebkar, A., & Barreto, G. E. Growth Factors and Neuroglobin in Astrocyte Protection Against Neurodegeneration and Oxidative Stress. Molecular neurobiology, 56(4), 2339–2351. https://doi.org/10.1007/s12035-018-1203-9. 2019 82. Hidalgo-Lanussa, O., Baez-Jurado, E., Echeverria, V., Ashraf, G. M., Sahebkar, A., Garcia-Segura, L. M., Melcangi, R. C.,

& Barreto, G. E. Lipotoxicity, neuroinflammation, glial cells and oestrogenic compounds. Journal of neuroendocrinology, 32(1), e12776. doi.org/10.1111/jne.12776. 2020 83. Iarkov A, Barreto GE, Grizzell J. A, and Echeverria V. Strategies for the Treatment of Parkinson's Disease: Beyond Dopamine. Front. Aging Neurosci. 12:4.doi:10.3389/ fnagi.2020.0000431. 2020 84. Oliveros-Matus P, Perez-Urrutia N, Alvarez-Ricartes N, Echeverria F, Barreto G. E. Elliot J, Iarkov A, and Echeverria V. Cotinine enhances fear extinction and astrocyte survival by mechanisms involving the nicotinic acetylcholine receptors signaling. Front Pharmacol. 11:303.doi:10.3389/fphar.2020.00303.eCollection. 2020 85. Liu Y, Echeverria V, Xu Y. Editorial: Medicinal Plants for Cardiovascular and Neurodegenerative Aging-Related Diseases: From Bench to Bedside. Front Pharmacol.11:585155. doi: 10.3389/fphar.2020.585155. eCollection 2020 86. Cabezas R, Sahebkar A, Echeverria V, Santos, J. G, AshrafmG. M., & Barreto, G. E. In Silico Identification of Novel Interactions for FABP5 (Fatty Acid-Binding Protein 5) with Nutraceuticals: Possible Repurposing Approach. Advances in experimental medicine and biology, 1308, 589–599. doi.org/10.1007/978-3-030-64872-5_29. 2021 87. Echeverria V, Echeverria F, Barreto GE, Echeverría J, Mendoza C. Estrogenic Plants: to Prevent Neurodegeneration and Memory Loss and Other Symptoms in Women After Menopause. Front Pharmacol. 2021 May 20; 12:644103. doi: 10.3389/fphar.2021.644103. eCollection PMID: 340*****-****. 88. Barreto GE, Gonzalez J, Reiner Ž, Jamialahmadi T, Echeverria V, Ashraf GM, Sahebkar A. In silico interactions of statins with cell death-inducing DNA fragmentation factor-like effector A (CIDEA). Chem. Biol. Interact. 109528.

Contact this candidate